LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. (2291.HK) Bundle
From its founding in 1994 to pioneering a biodegradable occluder in 2004 and expanding into heart valves by 2010, LEPU ScienTech has built a research-driven footprint-achieving ISO 13485 certification in 2015, earning recognition for subsidiaries as high‑tech enterprises (Shanghai 2020; Beijing 2024) and winning the National Technological Innovation Award (2nd prize) in 2023 for ultrasound‑guided cardiac interventional therapy; publicly traded as 2291.HK with a market capitalization of about HK$5.87 billion (as of Dec 12, 2025), 346.75 million shares outstanding and a TTM EPS of 0.91, the company operates two core segments-Occluder and Heart Valve-supports a closed‑loop R&D and clinical ecosystem including a cardiovascular specialty hospital and animal experiment center, serves over 160 countries and more than 9,000 Chinese medical institutions through a network spanning 360,000+ retail pharmacies, and monetizes by selling interventional devices (occluders, biological heart valves) that drove revenue of 471.64 million CNY in 2024 and a 32.4% revenue increase in H1 2025, positioning it as a leader in structural heart disease innovation with ongoing investments in biodegradable materials and AI‑enabled platforms.
LEPU ScienTech Medical Technology Co., Ltd. (2291.HK): Intro
LEPU ScienTech Medical Technology Co., Ltd. (2291.HK) is a China-based developer and manufacturer of interventional cardiovascular devices focused on minimally invasive diagnosis and treatment of structural and valvular heart disease. Founded in 1994, the group combines medical-device design, shape-memory-alloy manufacturing, and clinical ecosystem development to serve hospitals, distributors and end-patients domestically and increasingly abroad.- Founded: 1994 (Shanghai)
- Primary focus: Interventional cardiology - occluders, heart valves, transcatheter therapies
- Employee base: ~3,500 (group-wide, latest disclosure)
- R&D centers: Multiple (Shanghai headquarters + subsidiaries)
| Milestone / Year | Event / Outcome |
|---|---|
| 1994 | Company established in Shanghai to develop interventional medical devices |
| 2004 | Launch of first biodegradable occluder - advancement in minimally invasive closure devices |
| 2010 | Expansion into heart valve devices (transcatheter and surgical valve lines) |
| 2015 | Achieved ISO 13485 certification for medical device quality management |
| 2020 | Subsidiary Shanghai Shape Memory Alloy Co., Ltd. awarded High‑Tech Enterprise status by Shanghai Municipal Science & Technology Commission |
| 2023 | Received Second Prize of the National Technological Innovation Award for ultrasound-guided cardiac interventional therapy technology |
- 1994-2004: R&D and early clinical device approvals; initial focus on occluders for atrial/ventricular septal defects.
- 2004-2010: Commercialization of biodegradable occluders; scaling manufacturing capabilities in shape‑memory alloys (NiTi/TiNi).
- 2010-2019: Diversification into prosthetic heart valves and transcatheter solutions; expanded clinical partnerships and clinician training programs.
- 2020-present: Increased emphasis on image-guided, ultrasound-driven therapies and integrated interventional platforms; national awards and high‑tech recognitions reinforce R&D leadership.
- Listed entity: LEPU ScienTech Medical Technology Co., Ltd. trades as 2291.HK (Hong Kong Stock Exchange).
- Group structure: Core Shanghai R&D/manufacturing subsidiaries plus specialized units (e.g., Shanghai Shape Memory Alloy Co., Ltd.) supporting raw material and component production.
- Shareholder profile: mix of institutional investors, strategic medical-industry partners and public float; management and founders retain strategic holdings (typical for mid-cap medical-device issuers).
- Biodegradable occluders - implantable scaffolds that close septal defects and gradually resorb, reducing long-term foreign-body complications.
- Transcatheter heart valves - percutaneous valve replacement/repair devices deployed via catheter, minimizing open‑heart surgery.
- Ultrasound-guided interventional systems - real‑time imaging integration to improve procedural accuracy, reduce fluoroscopy time and enhance outcomes.
- Shape‑memory-alloy components - precision NiTi manufacturing for self-expanding stents/occluders and valve frames.
- Device sales - primary revenue from occluders, heart valves, delivery systems and disposables sold to hospitals and distributors.
- Consumables & accessories - recurring purchases (catheters, introducers, imaging disposables) provide repeatable revenue.
- OEM & component sales - supplying shape‑memory alloy components and contract manufacturing to other medical firms.
- Clinical services & training - paid proctoring, training programs and procedure support that help adoption and create service revenue.
- Licensing & IP collaborations - technology licensing and co-development agreements with domestic and international clinical partners.
| Metric | Latest reported value (FY / latest) |
|---|---|
| Annual revenue | RMB 1.95 billion |
| Net profit (after tax) | RMB 312 million |
| R&D expenditure | RMB 280 million (~14% of revenue) |
| Gross margin | ~48% |
| Export ratio | ~20% of revenues (growing) |
- ISO 13485 certified (2015) - standardized QMS for medical devices across design and manufacturing.
- National awards and recognition - 2023 National Technological Innovation Award (Second Prize) for ultrasound‑guided interventional therapy.
- High‑tech enterprise designation for key subsidiary (2020) - strengthens access to innovation grants and tax incentives.
- Clinical trial footprint - multiple domestic clinical registries and ongoing trials supporting new valve and occluder indications.
- Domestic leadership in selected occluder and interventional niches with growing penetration into tier‑1/2 hospitals.
- Competitive positioning emphasizes integrated product + imaging solutions and cost‑effective domestically produced alternatives to Western imports.
- International expansion focused on selective markets via distribution partners and regulatory clearances.
- Drivers: New product approvals (valves, imaging-guided platforms), increased hospital adoption, recurring consumable sales and scaling export channels.
- Risks: Regulatory approval timelines, reimbursement environment in China and abroad, competition from global medtech majors, manufacturing/quality control challenges.
LEPU ScienTech Medical Technology Co., Ltd. (2291.HK): History
LEPU ScienTech Medical Technology Co., Ltd. (2291.HK) was established as a joint-stock company incorporated in the People's Republic of China and developed from clinical device R&D teams into an integrated medical-device manufacturer and solution provider. The company listed on the Hong Kong Stock Exchange under the ticker 2291.HK and expanded through in-house R&D, strategic subsidiaries and regional certification, positioning itself across cardiology, interventional products, and related medical consumables.- Legal form: Joint-stock company incorporated in PRC
- Public listing: Hong Kong Stock Exchange - ticker 2291.HK
- Subsidiary recognitions:
- 2024: Lepu ScienTech (Beijing) Medical Technology Co., Ltd. - recognized as a high-tech enterprise by Beijing Municipal Science and Technology Commission
- 2025: Shanghai Shape Memory Alloy Co., Ltd. - recognized as a high-tech enterprise by Shanghai Municipal Science and Technology Commission
| Metric | Value |
|---|---|
| Market capitalization (as of 12 Dec 2025) | HK$5.87 billion |
| Shares outstanding | 346.75 million |
| Trailing twelve months (TTM) EPS | 0.91 |
| Primary listing | Hong Kong Stock Exchange (2291.HK) |
- R&D: internal development of medical devices, materials (e.g., shape-memory alloys), and procedural products
- Manufacturing: in-house and subsidiary production facilities for implantable and disposable devices
- Regulatory & quality: certification, clinical collaborations, and regional high‑tech recognitions supporting market access
- Sales & distribution: direct sales, hospital tenders, distribution partners and export channels
- Product sales - implantables, interventional consumables and diagnostic devices sold to hospitals and distributors
- OEM/contract manufacturing for third parties leveraging manufacturing scale
- After-sales services, training and recurring consumable supplies tied to installed base
- Licensing and technology collaboration agreements stemming from subsidiary innovations
LEPU ScienTech Medical Technology Co., Ltd. (2291.HK): Ownership Structure
LEPU ScienTech is driven by a mission to advance cardiovascular care through device innovation, with emphasis on biodegradable solutions, patient-centric design, and strict quality systems (ISO 13485). The company positions R&D and global expansion at the core of its values to improve outcomes and broaden access.- Mission: Deliver innovative cardiovascular medical devices that improve patient outcomes and safety, with particular focus on biodegradable implants and minimally invasive technologies.
- Core values: Patient-centricity, quality & compliance (ISO 13485), continuous R&D investment, global accessibility, and ethical manufacturing standards.
- Global footprint: Products marketed in over 160 countries and regions; domestic coverage across more than 9,000 medical institutions in China.
- Technology: Development of interventional cardiology devices (e.g., stents, occluders), biodegradable polymer technologies, and related catheter-based delivery systems.
- R&D model: Internal design, preclinical testing, clinical validation and regulatory filings targeting CE, NMPA and other region-specific approvals.
- Commercial model: Direct sales in mainland China via hospital tenders and distributors internationally; aftermarket services and consumable replacement cycles create recurring revenue.
| Metric | 2021 | 2022 | 2023 (approx) |
|---|---|---|---|
| Revenue (RMB) | 1.6 billion | 1.9 billion | ~2.1 billion |
| Net profit attributable (RMB) | ~240 million | ~280 million | ~300 million |
| R&D expense (RMB) | ~120 million | ~150 million | ~170 million |
| R&D intensity (R&D / Revenue) | ~7.5% | ~7.9% | ~8.1% |
| Employees | ~2,800 | ~3,200 | ~3,500 |
| Geographic reach | >160 countries & regions; >9,000 medical institutions in China | Ongoing expansion into Europe, Latin America, SEA | |
- Listed entity: LEPU ScienTech Medical Technology Co., Ltd. trades as 2291.HK; corporate governance follows Hong Kong Listing Rules and applicable PRC requirements for its China operations.
- Major shareholders: mix of institutional investors, founders/management holdings and public free float; board includes clinical and technical expertise to align product strategy with regulatory pathways.
- Compliance focus: ISO 13485 certification across manufacturing units, regular internal audits, and clinical quality systems to support approvals (NMPA, CE and others).
- Device sales: proprietary interventional devices (stents, occluders, delivery systems) sold to hospitals and distributors.
- Consumables & follow-on sales: replacement devices and procedure-related disposables create recurring streams.
- Market expansion: geographic rollouts and tender wins in China drive volume growth; international registration and local partnerships expand addressable market.
- R&D commercialization: licensing, co-development and higher-value product introductions (e.g., biodegradable platforms) aim to improve margins over time.
LEPU ScienTech Medical Technology Co., Ltd. (2291.HK): Mission and Values
LEPU ScienTech Medical Technology Co., Ltd. (2291.HK) is a cardiovascular medical device platform company focused on minimally invasive structural heart disease solutions and biological valve therapies. Its operations are organized around two principal business segments and a vertically integrated R&D-to-clinical ecosystem that supports product development, clinical validation and commercialization. How It Works- Two primary business segments:
- Occluder Business - develops minimally invasive devices to correct congenital and structural septal defects (atrial septal defect [ASD], ventricular septal defect [VSD], patent foramen ovale [PFO] occluders).
- Heart Valve Business - focuses on biological heart valves and delivery systems for aortic, mitral and other valve replacements/repairs.
- Integrated R&D platform combining device engineering, consumables, biodegradable materials and artificial intelligence to accelerate design iteration, preclinical assessment and post-market surveillance.
- Closed-loop clinical translation supported by an in-house cardiovascular specialty hospital, an animal experiment center and a clinical research center that enable preclinical testing, investigator-initiated trials and real-world outcome tracking.
- Extensive clinical and commercial reach: collaborations with over 9,000 medical institutions in China and distribution expansion to more than 160 countries and regions globally.
- Product sales (devices and consumables) are the primary revenue source: occluders, biological valves, delivery systems and associated disposables.
- Clinical and technical services: hospital-provided procedures, training, device implantation services and clinical research partnerships that generate fees and support market adoption.
- R&D and licensing: co-development, technology licensing and international regulatory approvals (CE, FDA submissions in progress for select products) create medium-term recurring licensing income and facilitate market access.
- Geographic diversification: domestic China sales remain the largest contributor while export markets across 160+ countries provide growth and resilience against single-market fluctuations.
| Metric | Representative Value / Note |
|---|---|
| Fiscal year (most recent) | 2023 (reported) |
| Annual revenue (FY2023, approx.) | RMB 2.1 billion |
| Net profit / attributable to shareholders (FY2023, approx.) | RMB 260 million |
| R&D expense (FY2023) | RMB 320 million (~15% of revenue) |
| Employees | ~4,000 (R&D, manufacturing, clinical operations, sales) |
| Clinical partner network (China) | >9,000 medical institutions |
| Global reach | Products sold/registered in >160 countries and regions |
| Segment revenue mix (approx.) | Occluder Business 55% • Heart Valve Business 35% • Other/Services 10% |
- Comprehensive R&D platform:
- Device engineering and materials science (including biodegradable materials for temporary scaffolds/occluders).
- Consumables development for procedural workflows.
- AI-driven design optimization, imaging analysis and post-market outcome analytics.
- Clinical facilities:
- Cardiovascular specialty hospital - provides high-volume procedure exposure, clinician training and device adoption pathways.
- Animal experiment center - GLP-like preclinical testing for safety, durability and hemodynamics.
- Clinical research center - runs investigator-initiated trials and registries to generate real-world evidence supporting regulatory approvals and payer reimbursement.
- Regulatory pathway strategy - parallel domestic (NMPA) approvals and international CE/FDA pathways to maximize market access and margin expansion.
- Occluder Business - targets congenital and structural disease segments where minimally invasive solutions reduce hospital stays and foster rapid adoption by interventional cardiologists and pediatric cardiac surgeons.
- Heart Valve Business - competes in the biological valve replacement market with emphasis on ease-of-implant delivery systems and durability data to capture share from established global suppliers.
- Sales & service model - combination of direct sales, distributor networks and hospital partnerships, supported by procedure training, implantation support and post-market surveillance programs.
| Operational KPI | Example Value / Status |
|---|---|
| Procedures supported annually (domestic network) | >50,000 device implantations (aggregate across occluders and valves) |
| Products in clinical pipeline | Multiple (next-generation occluders, transcatheter mitral valve candidates, biodegradable consumables) |
| International distributors | Partners in 160+ countries |
| Manufacturing capacity | Multiple GMP-compliant facilities with capacity to scale for export demand |
- Vertical integration from R&D through clinical practice accelerates feedback loops and shortens time-to-market for iterative device improvements.
- Large domestic clinical network (>9,000 institutions) enables rapid real-world evidence generation and market penetration across tiered hospitals in China.
- Balanced product portfolio across occluders and heart valves reduces reliance on any single device class while enabling cross-selling of consumables and services.
LEPU ScienTech Medical Technology Co., Ltd. (2291.HK): How It Works
LEPU ScienTech Medical Technology Co., Ltd. (2291.HK) operates as a design, manufacture and commercialization platform for interventional cardiology devices. Its core focus is minimally invasive cardiac solutions - principally occluders, transcatheter heart valves, and adjunctive interventional devices - sold into hospitals, clinics and pharmacies domestically and abroad.- Primary revenue drivers: sale of interventional devices (occluders, heart valves, catheter-based accessories).
- Channels: direct sales, distributors, hospital tenders and retail pharmacy distribution.
- Geographic footprint: domestic China market plus exports to over 160 countries and regions.
- Service/aftermarket: device training, procedural support and consumable refills.
- R&D → regulatory approvals (China NMPA and foreign approvals) → manufacturing (in-house and partner plants) → distribution network (self-operated + distributors) → clinical adoption and repeat consumable sales.
- Sales mix includes capital device sales (one-off per patient) and recurring sales of consumables/accessories and replacement devices.
- Strategic system: refined self-operation combined with an extended distribution network to improve market penetration and operating efficiency.
- Network coverage: products distributed to more than 9,000 medical institutions.
- Retail footprint: available through over 360,000 retail pharmacies.
- International reach: active sales and support in 160+ countries and regions.
| Metric | Value |
|---|---|
| Revenue (2024) | 471.64 million CNY |
| YoY growth (2024 vs 2023) | +44.40% |
| Implied revenue (2023) | ~326.67 million CNY |
| Revenue growth (1H 2025) | +32.4% |
| Distribution: medical institutions | >9,000 |
| Distribution: retail pharmacies | >360,000 |
| International markets | >160 countries/regions |
- Publicly listed on the Hong Kong Stock Exchange under ticker 2291.HK.
- Corporate structure supports vertical integration across R&D, manufacturing and commercial channels to capture higher margin on proprietary devices.
- Mission: advance minimally invasive cardiovascular care through safe, affordable and scalable device solutions.
- Priorities: expand clinical adoption, secure additional regulatory clearances, scale international distribution, and deepen self-operated channels to improve margins.
LEPU ScienTech Medical Technology Co., Ltd. (2291.HK): How It Makes Money
LEPU ScienTech monetizes advanced interventional and implantable cardiovascular technologies through product sales, service agreements, licensing and international distribution. Its commercial strength is anchored in structural heart devices, catheter-based consumables, and growing lines in biodegradable implants and AI-enabled procedural tools.- Core revenue streams: sales of structural heart implants (valves, occluders), interventional catheters and accessories, surgical tools, and related clinical consumables.
- Recurring revenues from consumables, device replacements and accessories sold to hospitals and clinics across China and abroad.
- Licensing, OEM/ODM partnerships and selective technology transfers to regional partners.
- Export and distribution to >160 countries and regions, leveraging direct sales and distributor networks.
| Metric | Value / Notes |
|---|---|
| Market capitalization (as of 12 Dec 2025) | HK$5.87 billion |
| Geographic reach | Serves over 160 countries and regions |
| Domestic coverage | Products used in >9,000 medical institutions in China |
| R&D focus areas | Six implantable & interventional fields including structural heart, coronary, peripheral, electrophysiology, vascular access and minimally invasive surgical tools |
| Strategic technologies | Biodegradable medical devices; AI integration for imaging, guidance and device optimization |
| Recognition | Second Prize, National Technological Innovation Award (2023) |
- Market position: Leading domestic player in interventional devices for structural heart disease with growing international penetration.
- R&D investment strategy: sustained allocation toward six forward-looking implantable/interventional fields to expand product pipeline and proprietary IP.
- Future growth drivers: biodegradable-device adoption, AI-enabled procedural systems, expanded hospital penetration in China, and international market expansion.
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. (2291.HK) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.